This page contains a Flash digital edition of a book.
Gastrointestinal Cancer


Vater – results of a controlled, prospective, randomized multicentre study, Eur J Cancer, 1993;29A:698–703.


132. Klinkenbijl JH, Jeekel J, Sahmoud T, et al., Adjuvant radiotherapy and 5-fluorouracil after curative resection of cancer of the pancreas and periampullary region: phase III trial of the EORTC gastrointestinal tract cancer cooperative group, Ann Surg, 1999;230:776–82, discussion 782–4.


133. Neoptolemos JP, Dunn JA, Stocken DD, et al.; European Study Group for Pancreatic Cancer, Adjuvant chemoradiotherapy and chemotherapy in resectable pancreatic cancer: a randomised controlled trial, Lancet, 2001;358:1576–85.


134. Neoptolemos JP, Stokken DD, Friess H, et al.; European Study Group for Pancreatic Cancer, A randomized trial of chemoradiotherapy and chemotherapy after resection of pancreatic cancer, N Engl J Med, 2004;350:1200–10.


135. Burris HA 3rd, Moore MJ, Andersen J, et al., Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial, J Clin Oncol, 1997;15:2403–13.


136. Oettle H, Post S, Neuhaus P, et al., Adjuvant chemotherapy with gemcitabine vs observation in patients undergoing curative-intent resection of pancreatic cancer: a randomized controlled trial, JAMA, 2007;297:267–77.


137. Neuhaus P, Riess H, Post S, et al., CONKO-001: Final results of the randomized, prospective, multicenter phase III trial of adjuvant chemotherapy with gemcitabine versus observation with resected pancreatic cancer, J Clin Oncol, 2008;26(Suppl. 20):abstract LBA4504.


138. Ueno H, Kosuge T, Matsuyama Y, et al., A randomised phase III trial comparing gemcitabine with surgery-only in patients with resected pancreatic cancer: Japanese Study Group of Adjuvant Therapy for Pancreatic Cancer, Br J Cancer, 2009;101:908–15.


139. Regine WF, Winter KA, Abrams RA, et al., Fluorouracil vs gemcitabine chemotherapy before and after fluorouracil- based chemoradiation following resection of pancreatic adenocarcinoma: a randomized controlled trial, JAMA, 2008;299:1019–26.


140. Neoptolemos J, Büchler M, Stocken DD, et al., A multicenter, international, open-label, randomized, controlled phase III trial of adjuvant 5-fluorouracil/folinic acid (5-FU/FA) versus gemctabine (GEM) in patients with resected pancreatic ductal adenocarcinoma, J Clin Oncol, 2009;27(Suppl. 18):


abstract LBA4505.


141. Beger HG, Link KH, Gansauge F, Intraarterial adjuvant chemotherapy after pancreticoduodenectomy : significant reduction in occurrence of liver metastasis, World J Surg, 1999;23:946–9.


142. Pendurthi TK, Hoffman JP, Ross E, et al., Preoperative versus postoperative chemoradiation for patients with resected pancreatic adenocarcinoma, Am Surg, 1998;64:686–92.


143. Hoffman JP, Lipsitz S, Pisansky T, et al., Phase II trial of preoperative radiation therapy and chemotherapy for patients with localized, resectable adenocarcinoma of the pancreas : an Eastern Cooperative Oncology Group Study, J Clin Oncol, 1998;16:317–23.


144. Breslin TM, Hess KR, Harbison DB, et al., Neoadjuvant chemoradiotherapy for adenocarcinoma of the pancreas: treatment variables and survival duration, Ann Surg Oncol, 2001;8:123–32.


145. White R, Lee C, Anscher M, et al., Preoperative chemoradiation for patients with locally advanced adenocarcinoma of the pancreas, Ann Surg Oncol, 1999;6:38–45.


146. Nukui Y, Picozzi VJ, Traverso LW, Interferon-based adjuvant chemoradiation therapy improves survival after pancreaticoduodenectomy for pancreatic adenocarcinoma, Am J Surg, 2000;179:367–71.


147. Picozzi VJ, Abrams RA, Decker PA, et al.; for the American College of Surgeons Oncology Group, Multicenter phase II trial of adjuvant therapy for resected pancreatic cancer using cisplatin, 5-fluorouracil, and interferon-alfa-2b- based chemoradiation: ACOSOG Trial Z05031, Ann Oncol, 2011;22:348–54.


148. Yeo CJ, Abrams RA, Grochow LB, et al.,


Pancreaticoduodenectomy for pancreatic adenocarcinoma :postoperative adjuvant chemoradiation improves survival. A prospective single-institution expeerience, Ann Surg, 1997;225:621–33.


149. Spitz FR, Abbruzzese JL, Lee JE, et al., Preoperative and postoperative chemoradiation strategies in patients treated with pancreaticoduodenectomy for adenocarcinoma of the pancreas, J Clin Oncol, 1997;15:928–37.


150. Bergenfeldt M, Albertsson M, Current state of adjuvant therapy in resected pancreatic adenocarcinoma, Acta Oncol, 2006;45:124–35.


151. Staley CA, Lee JE, Cleary KR, et al., Preoperative chemoradiation, pancreaticoduodenectomy, and intraoperative radiation therapy for adenocarcinoma of the pancreatic head, Am J Surg, 1996;171:118–24.


152. Ishikawa O, Ohigashi H, Imaoka S, et al., Concomitant benefit of preoperative irradiation in preventing pancreas fistula formation after pancreatoduodenectomy, Arch Surg, 1991;126:885–9.


153. Lowy AM, Lee JE, Pisters PW, et al., Prospective, randomized trial of octreotide to prevent pancreatic fistula after pancreaticoduodenectomy for malignant disease, Ann Surg, 1997;226:632–41.


154. Pisters PW, Abbruzzese JL, Janjan NA, et al., Rapid- fractionation preoperative chemoradiation, pancreaticoduodenectomy, and intraoperative radiation therapy for resectable pancreatic adenocarcinoma, J Clin Oncol, 1998;16:3843–50.


155. Snady H, Bruckner H, Cooperman A, et al., Survival advantage of combined chemoradiotherapy compared with resection as the initial treatment of patients with regional pancreatic carcinoma. An outcomes trial, Cancer, 2000;89:314–27.


156. White R, Lee C, Anscher M, et al., Preoperative chemoradiation for patients with locally advanced adenocarcinoma of the pancreas, Ann Surg Oncol, 1999;6:38–45.


157. White RR, Hurwitz HI, Morse MA, et al., Neoadjuvant chemoradiation for localized adenocarcinoma of the pancreas, Ann Surg Oncol, 2001;8:758–65.


158. Pisters PW, Wolff RA, Janjan NA, et al., Preoperative paclitaxel and concurrent rapid-fractionation radiation for resectable pancreatic adenocarcinoma: toxicities, histologic response rates, and event-free outcome, J Clin Oncol, 2002;20:2537–44.


159. White RR, Paulson EK, Freed KS, et al., Staging of pancreatic cancer before and after neoadjuvant chemoradiation, J Gastrointest Surg, 2001;5:626–33.


160. Bjerregaard JK, Mortensen MB, Jensen HA, et al., Long-term results of concurrent radiotherapy and UFT in patients with locally advanced pancreatic cancer, Radiother Oncol, 2009;92:226–30.


161. Köninger J, Wente MN, Müller-Stich BP, et al., R2 resection in pancreatic cancer – does it make sense?, Langenbecks Arch Surg, 2008;393:929–34.


42


EUROPEAN ONCOLOGY & HAEMATOLOGY


Page 1  |  Page 2  |  Page 3  |  Page 4  |  Page 5  |  Page 6  |  Page 7  |  Page 8  |  Page 9  |  Page 10  |  Page 11  |  Page 12  |  Page 13  |  Page 14  |  Page 15  |  Page 16  |  Page 17  |  Page 18  |  Page 19  |  Page 20  |  Page 21  |  Page 22  |  Page 23  |  Page 24  |  Page 25  |  Page 26  |  Page 27  |  Page 28  |  Page 29  |  Page 30  |  Page 31  |  Page 32  |  Page 33  |  Page 34  |  Page 35  |  Page 36  |  Page 37  |  Page 38  |  Page 39  |  Page 40  |  Page 41  |  Page 42  |  Page 43  |  Page 44  |  Page 45  |  Page 46  |  Page 47  |  Page 48  |  Page 49  |  Page 50  |  Page 51  |  Page 52  |  Page 53  |  Page 54  |  Page 55  |  Page 56  |  Page 57  |  Page 58  |  Page 59  |  Page 60  |  Page 61  |  Page 62  |  Page 63  |  Page 64  |  Page 65  |  Page 66  |  Page 67  |  Page 68  |  Page 69  |  Page 70  |  Page 71  |  Page 72  |  Page 73  |  Page 74  |  Page 75  |  Page 76  |  Page 77  |  Page 78  |  Page 79  |  Page 80  |  Page 81  |  Page 82  |  Page 83  |  Page 84  |  Page 85  |  Page 86  |  Page 87  |  Page 88  |  Page 89  |  Page 90  |  Page 91  |  Page 92